Objectives: The distribution and impact of various aeroallergens on asthma occurrence vary across regions. We investigated the association between sensitisation to perennial aeroallergens and asthma risk in children and adolescents in Yaounde, Cameroon.
Methods: This was a case-control study involving children and adolescents with asthma (cases) vs. non-allergic counterparts (controls). Children/adolescents with doctor-diagnosed asthma were included over a period of 30 months, and controls were selected from the community through random sampling. Logistic regression models were used to relate perennial aeroallergens sensitisation with asthma.
Results: The asthma and control groups included, respectively, 151 and 372 participants, with no sex ratio difference. The mean age (standard deviation) was 11.9 (4.4) years in cases and 11.3 (3.7) years in controls. The prevalence of sensitisation to any aeroallergen (cases vs. controls) was 76.8% (116/151) and 32.3% (120/372), p < 0.001. Sensitisation to mites was found in 104 (68.9%) cases vs. 56 (15.1%) controls, p < 0.001. In multivariable analysis, sensitisation to Alternaria alternata, Blattella germanica and dander (cat and dog) was not associated with asthma. However, sensitisation to mites was significantly associated with asthma. Odds ratios (95% CI) for sensitisation to Dermatophagoides pteronyssinus, Dermatophagoides farinae and Blomia tropicalis in relation with asthma were 7.28 (3.75-14.15), 2.65 (1.27-5.45) and 3.23 (1.68-6.21), respectively.
Conclusions: Sensitisation to mites was the main perennial allergenic factor associated with asthma in children and adolescents in this setting. This has application for the selection of patients with asthma who could benefit from the control of exposure to mites and specific immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/02770903.2014.995306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tezepelumab for severe asthma: elevating current practice to recognize epithelial driven profiles.
Respir Res
October 2024
Allergy Unit and Asthma Center, Integrated University Hospital of Verona, Verona, Italy.
Article Synopsis
- Tezepelumab is a medication that targets TSLP, an important cytokine related to the epithelium, and has been shown to effectively reduce asthma symptoms in patients, regardless of their asthma type or phenotype.
- The text emphasizes the link between environmental factors, epithelial barrier dysfunction, and asthma control, highlighting how allergies and specific exposures can worsen symptoms due to impaired immune responses.
- Clinical studies show that tezepelumab not only reduces asthma exacerbations linked to allergens but also decreases mucus plugging and improves lung function, suggesting its significant role in treating epithelial-driven asthma.
Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients.
Ann Med
December 2024
Department of Medical and Surgical Science, Universidad de las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Article Synopsis
- - Dupilumab is a new medicine that helps people with severe nasal issues and asthma, and this study looked at how it works for patients who have or haven’t used similar medicines before.
- - The study involved 42 patients, most of whom had asthma, and measured their symptoms and health after 12 months of using dupilumab.
- - Results showed that dupilumab made a big difference in improving patients' symptoms, reducing nasal polyp size, and making overall health better for everyone, no matter their previous treatment history.
Optimizing Identification of Allergic Sensitization to Seasonal Inhalant Allergens in the USA: Implications for Constructing Optimal Panels to Evaluate Patients with Allergy.
Int Arch Allergy Immunol
September 2024
Quest Diagnostics, Secaucus, New Jersey, USA.
Introduction: While a specific number and type of antigens are recognized to detect perennial inhalant allergies, the optimal number and combination of allergens to reliably identify seasonal allergic sensitization is unclear due to limited national data. This study analyzed aeroallergen testing data from a large US clinical reference laboratory to provide guidance for optimizing seasonal allergen test selection.
Methods: The 2019 serum IgE tests for seasonal inhalant allergens were identified from the Quest Diagnostics database.
A modified schedule of multiple aeroallergen ultra-rush immunotherapy in perennial allergic rhinitis: safety, efficacy, and T lymphocyte cell population studies.
Allergol Immunopathol (Madr)
May 2024
Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;
Background: This study assessed whether a modified immunotherapy schedule for allergic rhinitis could be safe and efficient. Ultra-rush immunotherapy (URIT) rapidly desensitizes patients to aeroallergens.
Objective: We aimed to develop a modified URIT protocol in 3 days to achieve the target dose while observing whether it could improve this situation and decrease the time to achieve the maintenance dose.
Allergic Rhinitis: A Review.
JAMA
March 2024
Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Importance: Allergic rhinitis affects an estimated 15% of the US population (approximately 50 million individuals) and is associated with the presence of asthma, eczema, chronic or recurrent sinusitis, cough, and both tension and migraine headaches.
Observations: Allergic rhinitis occurs when disruption of the epithelial barrier allows allergens to penetrate the mucosal epithelium of nasal passages, inducing a T-helper type 2 inflammatory response and production of allergen-specific IgE. Allergic rhinitis typically presents with symptoms of nasal congestion, rhinorrhea, postnasal drainage, sneezing, and itching of the eyes, nose, and throat.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!